ArticleVaccines2023

A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years of Age.

Xin Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.